Urology Search
Urology Urology
benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.

Introduction

  • Histopathological diagnosis characterized by epithelial cell & smooth muscle proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, w/c may result in lower urinary tract symptoms, including voiding & storage symptoms
  • Common disease of aging men
  • Two phases where prostate doubles its size:
    • At puberty
    • 25 yr old & beyond

Etiology

  • The exact cause of benign prostatic hyperplasia (BPH) is still not well understood

Signs and Symptoms

  • Dribbling at the end of urination
  • Nocturia
  • Pain after ejaculation or urination
  • Weak or interrupted urine stream
  • Trouble starting a urine stream
  • Urinary frequency
  • Urinary urgency
  • Urinary retention
  • Urinary incontinence
  • Urine w/ unusual smell or color

Risk Factors

  • Age 40 years old & older
  • Family history of benign prostatic hyperplasia (BPH)
  • Medical conditions such as obesity, heart & circulatory disease, type 2 diabetes mellitus (DM)
  • Lack of physical exercise
Editor's Recommendations
Most Read Articles
Cyclophosphamide, effective in hormone-naïve patients with non-metastatic biochemical recurrent prostate cancer
01 Aug 2016
Metronomic cyclophosphamide is modestly effective, and may be a safe and non-expensive treatment alternative in hormone-naïve patients with non-metastatic biochemical recurrent prostate cancer, as stated in a prospective single-arm open-label phase II study.